Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...
The rise of infections caused by Mgen, C. auris, treatment-resistant E. coli, and more could become future public-health threats, experts say.
Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...
MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to ...
World NTM Day, observed annually on August 4, is a global awareness initiative led by NTM Info & Research (NTMir) to spotlight the rising impact of nontuberculous mycobacterial (NTM) lung disease —a ...
MIAMI, Aug. 4, 2025 /PRNewswire-HISPANIC PR WIRE/ — As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback